^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PRCC-TFE3 fusion

    i
    Other names: PRCC, Proline Rich Mitotic Checkpoint Control Factor, RCCP1, Papillary Renal Cell Carcinoma Translocation-Associated Gene Protein, Papillary Renal Cell Carcinoma (Translocation-Associated), Proline-Rich Protein PRCC, TPRC, PRCC, Proline Rich Mitotic Checkpoint Control Factor, TFE3 , Transcription Factor Binding To IGHM Enhancer 3, Class E Basic Helix-Loop-Helix Protein, Transcription Factor E Family, Member A, BHLHe33 , Transcription Factor For Immunoglobulin Heavy-Chain Enhancer 3, Transcription Factor For IgH Enhancer, Transcription Factor E3, RCCP2 , RCCX1, TFEA
    Entrez ID:
    7030; 5546
    Related biomarkers:
    Mutation
    Fusion
    Others
    7ms
    Exploring G-quadruplex structure in PRCC-TFE3 fusion Oncogene: Plausible use as anti cancer therapy for translocation Renal cell carcinoma (tRCC). (PubMed, J Biotechnol)
    Confocal microscopy of HEK293T cells transfected with the fusion transcript confirmed G-quadruplexes formation in cell. This investigation may shed light on G-quadruplex's functions in fusion genes and may help in the development of therapies specifically targeted against fusion oncogenes, which would enhance the capability of current tRCC therapy approach.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PRCC (Proline Rich Mitotic Checkpoint Control Factor)
    |
    PRCC-TFE3 fusion • TFE3 fusion
    over1year
    Establishment and Characterization of a TFE3-rearranged Renal Cell Carcinoma Cell Line (FU-UR-2) With the PRCC-TFE3 Fusion Transcript. (PubMed, Anticancer Res)
    Cultured FU-UR-2 cells continuously propagated over 90 passages and may provide a new permanent culture model to study pathogenetic mechanisms, investigate biological behavior, and develop new treatments such as molecular-targeting antitumor agents or immunological drugs for TFE3-rRCCs.
    Preclinical • Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PRCC (Proline Rich Mitotic Checkpoint Control Factor)
    |
    PRCC-TFE3 fusion • TFE3 fusion
    over2years
    Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma. (PubMed, Clin Transl Med)
    Androgen and AR function as facilitators in Xp11.2 tRCC progression and may be a novel therapeutic target for Xp11.2 tRCC. The combined use of AR antagonist MDV3100 and UCHL1 inhibitor 6RK73 increased both the SUMOylation and ubiquitination of the PRCC-TFE3 fusion protein.
    Journal
    |
    AR (Androgen receptor) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PRCC (Proline Rich Mitotic Checkpoint Control Factor)
    |
    PRCC-TFE3 fusion • TFE3 translocation • TFE3 fusion
    |
    Xtandi (enzalutamide) • 6RK73